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interpretations from different experts. Of 3,936 germline BRCA1 SNVs currently represented in 47 ClinVar, only 983 are classified by an expert panel as 'benign' or 'pathogenic' without 48 conflicting interpretations. 49 50 There are two major approaches for resolving VUS. The first approach, data sharing, relies on 51 the expectation that as BRCA1 is sequenced in increasing numbers of individuals 14 , the recurrent 52 observation of a specific variant in multiple individuals who either have or have not developed 53 breast and/or ovarian cancer will enable the definitive interpretation of that variant. However, 54 although this may be possible for some variants, given that the vast majority of potential SNVs 55 in BRCA1 are exceedingly rare 15, 16 and that the phenotype is incompletely penetrant, it may be 56 decades or centuries before sufficient numbers of humans are included in genotype-phenotype 57 studies to accurately quantify cancer risk for each individual rare variant. 58 59 The second approach, functional assessment, has spurred the development of diverse in vitro 60 assays for BRCA1 17 . As the homology-directed DNA repair (HDR) function of BRCA1 is key 61 for tumor suppression, one commonly used assay involves expressing a BRCA1 variant in cells 62
and assessing the integrity of the cells' HDR pathway via inducing repair of a double strand 63 DNA break in a fluorescent reporter construct 18, 19 . Other approaches include assays for 64 embryonic stem cell viability 20 , cell sensitivity to chemotherapeutic drugs 20 , binding to known 65 partners such as BARD1 18, 21 , and minigene-based splicing assays 22, 23 . Computational tools can 66 predict variant effects based on features such as amino acid conservation. However, although 67 many such metrics correlate with pathogenicity, at present no computational tool is sufficiently 68 accurate to be used for the clinical interpretation of newly observed BRCA1 variants in the 69 absence of genetic or experimental evidence 24, 25 . 70 71
Functional assessment of BRCA1 variants has historically been limited in several ways. Chiefly, 72 experimental studies are post hoc and have not kept pace with the scaling of BRCA1 sequencing 73 and the accumulation of VUS. Additionally, assays that express variants as cDNA-based 74 transgenes removed from their genomic context 18, 21 fail to assess effects on splicing or transcript 75 stability, as well as potential artifacts of overexpression 26 . Genome editing technologies provide 76 a means to overcome these challenges. Yet to our knowledge, genome editing has not yet been 77 applied to functionally characterize VUS in BRCA1 or other genes similarly linked to cancer 78 predisposition. 79 80
Here we set out to apply genome editing to measure the functional consequences of all possible 81
SNVs in BRCA1, regardless of whether they have been previously observed in a human. Given 82 BRCA1's immense size, this initial study focuses on 13 exons that encode the functionally 83 critical RING and BRCT domains. In each experiment, a single exon is subjected to 'saturation 84 genome editing' 27 , wherein all possible SNVs are simultaneously introduced to a haploid human 85 cell line in which BRCA1 is essential. Consequently, BRCA1 variants that result in nonfunctional 86 alleles are depleted over time, a selection that is quantified by deep targeted sequencing. We 87 optimized this method to obtain function scores for 3,893 SNVs, comprising 96.5% of all 88 possible SNVs in the targeted exons. These function scores are bimodally distributed and nearly 89 perfectly concordant with expert-based assessments of pathogenicity. We predict that our 90 functional classifications will be of immediate clinical utility, and argue that the scaling of this 91 4 relative to WT HAP1 (Fig. 2a) . Second, it is known that HAP1 cells can spontaneously revert to 138 diploidy 37 . Simply sorting HAP1 cells for 1N ploidy prior to editing improved reproducibility 139 (Extended Data Fig. 3c-e) . 140 141 We next performed optimized SGE experiments for each of the 13 targeted exons in 1N-sorted  142 HAP1-Lig4KO cells, testing nearly every possible SNV per exon in replicate (Fig. 2b) . 143 Functional effects of SNVs on survival were determined by targeted DNA sequencing of each 144 SNV library as well as the edited exon in gDNA harvested on day 5 and day 11 ( Fig. 2c-e) . 145 Additionally, targeted RNA sequencing of day 5 samples was used to determine how abundant 146 exonic SNVs were in BRCA1 mRNA (Fig. 2f) . Because these optimizations resulted in greater 147 reproducibility (Extended Data Fig. 4 Function scores for SNVs in these 13 BRCA1 exons were bimodally distributed (Fig. 2g) . All 165 nonsense SNVs scored below -1.25 (N = 138, median = -2.12), whereas 98.7% of synonymous 166 SNVs >3 bp from splice junctions scored above -1.25 (N = 544, median = 0.00). We classified 167 all SNVs as 'functional', 'non-functional', or 'intermediate' by fitting a two-component 168
Gaussian mixture model in which the parameters of the 'non-functional' distribution were based 169 on all nonsense SNVs and the 'functional' distribution based on synonymous SNVs not depleted 170 in RNA (Extended Data Fig. 7 ). We then used this model to estimate the probability of each 171 SNV's score being drawn from the non-functional distribution (P nf We also investigated the relationship between our function scores and SNV frequencies in large-214 scale databases of human genetic variation. Of 302 assayed SNVs that overlap with the Genome 215 Aggregation Database (gnomAD) 16 , higher allele frequencies were associated with higher 216 function scores (Fig. 3d) 40 , and Align-GVGD 41 , which are largely based on evolutionary 231 conservation and biochemical properties of missense variants, the modesty of these correlations 232 underscores the value of functional assays (Fig. 3e, Extended Data Fig. 9a-g ). ROC curve 233 analysis restricted to missense variants reveals that SGE-based function scores outperform these 234 metrics at predicting pathogenicity status in ClinVar (Extended Data Fig. 9h-l are likely mediated at the protein level (Fig. 5a ). Many residues that are sensitive to missense 251
SNVs not impacting RNA levels map to buried hydrophobic residues or to the zinc-coordinating 252 loops that are required for proper RING domain folding ( Fig. 5b-c) This is evidenced by an overrepresentation of non-functional SNVs near splice junctions, 262 including low scores for many SNVs at terminal G nucleotides of exons (Fig. 4) , non-functional 263 exonic SNVs with low mRNA levels that create new acceptor or donor sequences (SNVs 264 annotated with asterisks in Fig. 5d ), and the presence of short regions (~6-8 bp) in which many 265
SNVs have moderate-to-strong effects on RNA levels, suggestive of exonic splice enhancers 42 266 (Fig. 5e) . Certain exons appeared particularly prone to harbor non-functional SNVs with low 267 RNA scores. In exon 16, for instance, 46 of 244 SNVs (excluding nonsense) were non-functional 268 (Fig. 5e ). Of these, more than half (n = 26) reduced RNA levels by more than 2-fold, and nearly 269 a third (n = 15) by more than 4-fold. In contrast, in exon 19, of 55 of 234 SNVs (excluding 270 nonsense) that were non-functional, none lowered expression by more than 2-fold ( Fig. 5f) Array-synthesized oligos were designed as follows for each saturation genome editing 430 region (i.e. a BRCA1 exon). The sequence to be mutated (~100bp) was obtained from the human 431 genome (hg19) and a synonymous substitution was introduced at the chosen Cas9 target site (e.g. 432 a substitution at the PAM site). This 'fixed' substitution in the library was included in design to 433 serve multiple purposes: 1.) plasmid library molecules harboring the substitution are predicted to 434 be cleaved less frequently by Cas9:gRNA complexes, 2.) SNVs introduced to cells are predicted 435 to be depleted via Cas9 re-cutting less frequently as a consequence of the fixed substitution, and 436 3.) sequencing reads can be filtered on the fixed substitution to distinguish true SNVs introduced 437 via HDR from sequencing errors. A second synonymous substitution at an alternative CRISPR 438 target site was introduced to the sequence as well, such that each exon's SNV library would be 439 compatible with multiple gRNAs. Next, a sequence was created for every possible single 440 nucleotide substitution on this template. For all sequences, adapters were added to both ends to 441 enable PCR amplification from the oligo pool. For each SGE region, the total number of oligos 442 designed was three times the length of the region, plus the oligo template without any SNV (e.g. 443 for a 100 bp SGE region, 301 total oligos were designed puromycin were assessed 4 hours after plating to establish baseline absorbance for each target. 506
Cell survival was assessed at day 2, day 5, and day 7 post-transfection using the CellTiterGlow 507 reagent (Promega, 1:10 dilution of suggested reagent). Luminescence at 135 nm absorbance was 508 measured using a Synergy plate reader (Biotek Instruments). 509 510
Nucleic acid sampling and sequencing library production 511
For obtaining WT HAP1 genomic DNA for cloning homology arms and for genotyping 512 the HAP1-Lig4KO cell line, DNA was isolated using the DNeasy kit (Qiagen). For each SGE 513 experiment, DNA and total RNA were purified using the AllPrep kit (Qiagen). DNA samples 514
were quantified with the Qubit dsDNA Broad Range kit (Thermo Fisher) and RNA samples by 515 UV spectrometry (Nanodrop). PCR primers for genomic DNA were designed such that one 516 primer would anneal outside of the homology arm sequence, thereby selecting for amplicons 517 derived from gDNA and not plasmid DNA. PCR conditions were optimized using gradient qPCR 518 on WT HAP1 gDNA. 519
All gDNA harvested from the population of day 5 cells was sampled by performing many 520 PCR reactions in parallel on a 96-well plate, using 250 ng of gDNA per 50 ul reaction such that 521 all day 5 gDNA was used in PCR (Kapa HiFi). At least as many PCR reactions were performed 522 for day 11 samples (which yielded more gDNA) to ensure adequate sampling. PCRs were 523 performed for the minimal number of cycles needed to complete amplification, with cycling 524 conditions as specified in the Kapa HiFi protocol. An additional PCR was performed using day 5 525 gDNA from negative control transfections for each exon. 526
After PCR, multiple wells of amplicons from the same sample were pooled and purified 527 using Ampure beads. Next, a nested qPCR was performed using the first reaction as template to 528 produce a smaller amplicon with custom sequencing adapters ('PU1L' and 'PU1R'), which was 529 likewise purified with Ampure beads. The SGE libraries were also PCR-amplified at this step, 530 starting from 50 ng of plasmid DNA. Lastly, a final qPCR was performed using purified 531 products from the second reaction as template to add dual sample indexes and flow cell adapters. 532 RNA was sampled from day 5 HAP1-Lig4KO cells (AllPrep, Qiagen). Reverse 533 transcription followed by RNase H treatment was performed on all RNA harvested or a 534 maximum of 5 ug per sample (Superscript IV Kit, Life Technologies). This reaction was primed 535 with a gene-specific primer complementary to the 3' UTR in exon 23 of BRCA1. Primers were 536 14 designed for each exon to amplify across exon junctions, and reaction conditions were optimized 537 using gradient PCR. cDNA was distributed into 5 equal PCR reactions, which were run on a 538 qPCR machine and then pooled in equal ratios. Flow cell adapters and sample indexes were 539 added in an additional reaction (as for gDNA samples 'N' bases were removed. Reads from cDNA samples were removed if they contained indels or 558 did not perfectly match transcript sequence flanking each targeted exon. Remaining cDNA reads 559 were processed to match genomic DNA amplicons by removing flanking exonic sequence and 560 replacing it with the exon's corresponding intronic sequence. All reads were then aligned to 561 reference gDNA amplicons for each exon using the needleall command in the EMBOSS 6.4.0 562 package with the following parameters: '-gapopen 10 -gapextend 0.5 -aformat sam'. Reads not 563 aligning to the reference amplicon (alignment score < 300) were removed from analysis. To 564 analyze indels, unique cigar counts were quantified from day 5 and day 11 samples using a 565 custom Python script. Reads were classified as HDR events for rate calculations if the 566 programmed edit or edits to the PAM or protospacer (HDR marker edits) were observed in the 567 alignment. Variants without identifiable markers of HDR were not used. Abundances of SNVs 568 were quantified only from aligned reads that had no other mismatches or indels, with the 569 exception of the HDR markers. SNV reads with only the cut-site proximal HDR marker were 570 summed with reads that had both HDR markers to get total abundances for each SNV in each 571 sample, to which a pseudocount of 1 was added to all variants present in either the library, day 5 572 or day 11 sample. Frequencies for each SNV were calculated as SNV reads over total reads. 573 SNV measurements from WT HAP1 cells and HAP1-Lig4KO cells were processed separately at 574 all steps. 575 576
Modeling positional biases of library integration 577
Positional biases in editing rates were modeled for each SNV by using a LOESS 578 regression to fit the log2 day 5 over library ratios as a function of chromosomal position. To 579 avoid modeling biological effects instead of positional effects, the model was fit only on the 580 subset of SNVs that were not substantially depleted between any two timepoints in the 581 experiment (i.e. SNVs with day 5 over library ratios > 0.5 and day 11 over d5 ratios > 0.8. Custom scripts for analyzing sequencing data were written in Python and R. All code will 665 be made available upon request. 666 were transfected with a Cas9/gRNA plasmid either targeting the non-essential gene HPRT1 (control) or exon 17 of BRCA1 on day 0. Successfully transfected cells were selected with puromycin (days 1-4) and cultured until day 7, at which point cells were washed prior to imaging. Images are representative of two transfection replicates. c, The targeted BRCA1 exon 17 locus was deeply sequenced from a population of transfected cells sampled on day 5 and day 11. The fold-change from day 5 to day 11 for each editing outcome observed at a frequency over 0.001 in day 5 sequencing reads is plotted. All alleles but indel-free sequences and two in-frame insertions were depleted. d, Saturation genome editing experiments were designed to introduce all possible SNVs across thirteen BRCA1 exons encoding the protein's RING (exons 2-5) and BRCT domains (exons 15-23).
For each exon, a Cas9/gRNA construct was designed to be transfected with a library of plasmids containing all SNVs across ~10 0 bp of genomic sequence (the 'SNV library'). SNV libraries were designed to saturate a total of 1,345 bp of genomic sequence, spanning BRCT and RING domain coding regions and adjacent intronic sequences. SNV library plasmids contain homology arms to mediate genomic integration, as well as fixed synonymous variants within the CRISPR target site to prevent Cas9 re-cutting. Upon HAP1 cell transfection of each Cas9/gRNA plasmid / SNV library pair, successfully edited cells harbor a single BRCA1 SNV from the library. Cells are sampled 5 and 11 days after transfection and targeted gDNA and RNA sequencing is performed to quantify SNV abundances. SNVs compromising BRCA1 function are selected against, manifesting in reduced gDNA representation, and SNVs impacting mRNA production are depleted in RNA samples relative to gDNA. Variants observed in gDNA sequencing were included in this analysis if i) they aligned to the reference with either a single insertion or deletion within 15 bp of the predicted Cas9 cleavage site and ii) were observed at a frequency greater than 1 in 10,000 reads in both replicates. a, Histograms show the number of unique indels observed of each size, with negative sizes corresponding to deletions. More unique indels were observed in WT HAP1 cells compared to HAP1-Lig4KO cells for exons compared (WT data for exon 22 was excluded). b, Day 11 over day 5 indel frequencies were normalized to the median synonymous SNV in each replicate and then averaged across replicates to measure selection on each indel. The distribution of selective effects is shown for each experiment as a histogram, in which indels are colored by whether their size was divisible by 3 (i.e. 'in-frame' vs. 'frameshifting'). Whereas frameshifting variants were consistently depleted, some exons were tolerant to in-frame indels. The four leftmost columns show how SNV frequencies correlate between samples from within a single replicate experiment. The unusually high correlations between exon 22 SNV frequencies in the plasmid library and in day 5 gDNA samples from WT HAP1 cells suggests plasmid contamination in gDNA. Indeed, primer homology to a repetitive element in the exon 22 library was identified. Consequently, the WT HAP1 exon 22 data was removed from analysis and a different primer specific to gDNA was used to prepare exon 22 sequencing amplicons from HAP1-Lig4KO cells. The low HAP1-Lig4KO correlations between exon 18 SNV frequencies in day 5 gDNA and RNA and between RNA replicates suggests RNA sample bottlenecking consequential to low RNA yields. Therefore, exon 18 RNA was also excluded from analysis. Consistent with the higher rates of HDR-mediated genome editing (Fig. 2a) , replicate correlations (middle columns) were generally higher in HAP1-Lig4KO cells than WT HAP1 cells. CADD scores predict the deleteriousness of each SNV, and are therefore negatively correlated with function scores (rightmost columns). Exclude multinucleotide variants (SNVs within 2bp of an edited PAM site and likely to differ in consequence due to the edited PAM): 51 removed, 3,893 SNVs remain -SNV results in different codon change due to PAM edit (39) -SNV results in low RNA (>75% reduction) and is within 2 bp of PAM edit (2) --GT splice donor if not for PAM edit (10)
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Extended Data Figure 6 | SNV filtering to prevent erroneous functional classification. a, The flow chart describes filters used to produce the final SNV data set and shows how many SNVs were removed at each step. b, Raw day 5 over library SNV ratios are shown for a portion of exon 15 to illustrate how re-editing biases necessitate filtering. The three depleted SNVs marked with asterisks create alternative PAM sequences that likely allow the Cas9:gRNA complex to re-cut the locus and cause their removal. For other SNVs, the fixed PAM edit (a GGG to GCG synonymous change) minimalizes re-editing. The location of the target PAM is underlined and each indicated SNV is bolded in the annotations. The LOESS regression curve in shown in black. c,d, Plots show the relationship between day 5 over library and day 11 over day 5 ratios before (c) and after (d) filtering steps 1 and 2. Filtering removes outliers because editing biases primarily affect the day 5 over library ratio. e-g, Histograms show the distributions of function scores for SNVs deemed 'pathogenic' or 'benign' in ClinVar at different stages of filtering. Scores in e are derived prior to normalization across exons. and 'functional' SNVs plotted here were defined respectively as all nonsense SNVs and all synonymous SNVs with RNA scores within 1 SD of the median synonymous SNV. b, An ROC curve was generated using SGE function scores to distinguish the 634 'functional' and 'non-functional' SNVs defined in a. c, A two-component Gaussian mixture model was used to produce point estimates of the probability that each SNV was 'non-functional', P(nf), given its average function score across replicates. These Pvalues are plotted in d against function scores for a subset of the data. Thresholds were set such that P(nf) < 0.01 corresponds to 'functional', and P(nf) > 0.99 corresponds to 'non-functional', and 0.01 < P(nf) < 0. (Fig. 3b) , sensitivities and specificities for distinguishing 'Pathogenic'/'Likely pathogenic' from 'Benign'/'Likely benign' ClinVar annotations for each type of mutation are as follows: 92.7% and 92.9% for missense SNVs (N = 55), 100% and 100% for splice region SNVs (N = 23), and 95.2% sensitivity for canonical splice site SNVs (N = 83; specificity not calculable).
